Trial
NCT01000155
Efficacy of Vorinostat to Induce Fetal Hemoglobin in Sickle Cell Disease
Phase IITERMINATEDOPERATIONALConfidence: HIGH
Sponsor
Dana-Farber Cancer Institute
Collaborators
Brigham and Women's Hospital; Boston Children's Hospital; Merck Sharp & Dohme LLC
Condition
Sickle Cell Disease
Intervention
vorinostat
Why stopped
The study terminated early due to slow accrual.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2017-07-21